Inherited platelet function disorders (IPFDs) represent a significant fraction of congenital hemorrhagic disorders, and may be associated with bleeding of considerable severity. IPFDs may be difficult to diagnose and a preliminary accurate clinical examination and an objective evaluation of the severity of the bleeding history are manda- 
| INTRODUC TI ON
The crucial function of platelets in primary hemostasis is a finely regulated process, and a defect of any of the steps orchestrating the interaction of platelets with the vessel wall and regulating platelet activation leads to impaired blood clot formation and, consequently, to abnormal bleeding.
Inherited platelet function disorders (IPFDs) are rare congenital hemorrhagic disorders characterized by mild to severe mucocutaneous bleeding and by a wide phenotypic and genotypic heterogeneity.
Despite IPFDs make up a significant proportion of congenital bleeding diatheses, they remain poorly understood and often difficult to diagnose. The exact prevalence of IPFDs is unknown, but it may range from as low as 2/1 000 000 1 or for some autosomal recessive forms to up to 1/100 2 for some mild platelet secretion defects. The laboratory diagnosis of IPFD places a significant burden on hemostasis laboratories, with over 28 000 tests carried out yearly worldwide. 3 Moreover, the uninterrupted introduction of new laboratory tests and the ever-increasing discovery of novel forms further complicate the task of hematologic laboratories. The purpose of this review is to discuss the best way to identify patients with IPFDs and to outline a laboratory approach to diagnosis.
| IDENTIFI C ATI ON OF PATIENTS WITH A SUS PEC TED PL ATELE T FUN C TI ON DISORDER
The diagnostic approach to a patient with a bleeding disorder of suspected platelet origin should be based on the integration of a careful clinical evaluation and a panel of laboratory tests of increasing complexity. [3] [4] [5] [6] The first, and paradoxically most difficult, task is to decide whether bleeding is really abnormal and is due to an inherited condition related to a congenital molecular defect rather than to a local cause, to drug or food effects or to an acquired dysfunction.
Patients with a history of mucocutaneous bleeding (familial or not) for whom an acquired or drug-induced cause of platelet dysfunction was excluded, and for whom immune thrombocytopenia, von Willebrand disease, a blood clotting defect or afibrinogenemia have been ruled out, are eligible to undergo laboratory testing for
IPFDs.
A personal and family history of mucocutaneous bleeding helps to orient toward an IPFD, however, the absence of a familial bleeding history is not exclusive and recessive forms or a de novo mutation must be considered.
Especially for the mild forms, an accurate assessment of the presence and severity of bleeding symptoms using a standardized bleeding assessment tool (BAT) may be of great help. The ISTH-BAT 7 is a largely used tool, but it has not been sufficiently validated for patients with IPFDs yet. The bleeding tendency of IPFD may be widely variable, but excessive hemorrhage after surgery, trauma, dental extraction, or delivery are common and often serious. [8] [9] [10] Typical spontaneous bleedings are epistaxis, oral cavity bleeding, menorrhagia, and skin bruising, but rarely muscle hematomas, central nervous system bleeds, hematuria, gastrointestinal bleeding, and ovulation bleeding may occur. 6, 8 Moreover, some IPFDs may show peculiar hemorrhagic manifestations, like delayed bleeding exquisitely sensitive to antifibrinolytic drugs for the Quebec platelet disorder (QPD), postoperative or postpartum bleeding, trauma-related hematomas, and bleeding after tooth extraction, but rarely spontaneous hemorrhage, for the Scott syndrome.
Associated organ involvement should also be sought, given that some inherited platelet disorders are part of systemic syndromes.
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| Preliminary laboratory evaluation
Preliminary laboratory tests, including a full blood count, blood clotting (prothrombin time, partial thromboplastin time, fibrinogen), and von Willebrand factor (VWF) screening (VWF antigen, ristocetin cofactor activity, and factor VIII coagulant activity), should be performed before platelet function studies are started. A whole blood and differential count should be performed to exclude acquired hematologic disorders, but a mildly reduced platelet number should not preclude further testing because several IPFDs are associated with thrombocytopenia. [4] [5] [6] 11, 12 Once excluded other bleeding disorders, a series of laboratory investigations for possible IPFDs can be undertaken.
| Laboratory investigations of platelets
The first screening should include an evaluation of a blood smear, light transmission aggregometry (LTA), the measurement of platelet granule release and the evaluation of the main surface glycoproteins (GPs) by flow cytometry, 6 all assays now available in the majority of the hematology and hemostasis laboratories. 3 The analysis of Wright or May-Grünwald-Giemsa stained peripheral blood smear allows to gain information on platelet size (eg, giant platelets in Bernard Soulier syndrome) 13 20 In addition, other available tests are mepacrine release measured by flow cytometry, ortho-pthaldialdehyde assay, and ELISA methods to measure 5HT-release.
20
The release of α-granules is commonly evaluated by measuring surface P-selectin by flow cytometry after platelet activation.
However, the release of specific α -granule proteins (β -TG, TSP-1, VWF, fibrinogen, P-selectin) can also be assessed in platelet supernatants by HPLC or ELISA. Recently the ISTH platelet Physiology SSC has embarked on the project to generate a guidance on the measurement of platelet secretion.
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Flow cytometry for the measurement of glycoprotein receptor expression is crucial for the diagnosis of platelet adhesive protein defects, such as GT and BSS, and should be performed with resting platelets using antibodies toward the components of GPIIb/IIIa and GPIb/IX/V. Flow cytometry is highly recommended for the diagnosis of BSS and GT variant forms, in which LTA is normal. Platelet reactivity should be assessed using high and low concentrations of different agonists (eg: ADP, TRAP6, U46619) in suboptimal and optimal concentrations by quantifying surface expression of activation markers CD62P and CD63 as well as the binding of PAC-1 antibody to the high-affinity conformation of the fibrinogen receptor.
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A second set of laboratory tests, to be performed in patients for whom the first step has not yielded a conclusive diagnosis, should include LTA with an expanded range of agonists, flow cytometry with antibodies directed toward additional surface GPs, granule content, clot retraction, serum TxB 2, and transmission electron microscopy (TEM). 4, 5, 22 The measurement of the δ-granules content is assessed by lumi- Platelet TEM is recommended at this stage for counting granules and/or for the identification of structural alterations. 4, 5 Finally, the very special cases still evading diagnosis and for which a strong clinical suspicion persists may be studied with a series of additional, highly specialized, third step tests 6 ( Table 1 ).
| Point-of-care testing
This category includes automated or semi-automated tests which may be performed at the bedside, by non skilled personnel and that are in principle rapid and easy to use, employing whole blood without the need of sample processing. These include the platelet function ana- has been applied to the diagnosis of congenital defects of the platelet P2Y 12 receptor. 23 Platelet function methods combined with viscoelastic tests have been proposed as useful supplements to the existing platelet function tests that provide the advantages of rapidity and possibility to study platelet function in a physiologic environment (whole blood), but further studies are required to define their potential diagnostic application. 24 However, these tests are not available to most clinical laboratories and are limited to specialized laboratories.
| Molecular genetic analysis
The search for the causative variant by molecular genetic analysis is an increasingly used tool for the initial diagnosis of IPFD. 6, 25, 26 Genotyping is recommended for conditions in which a genotype/phenotype correlation has been established, 5 for those in which the laboratory platelet function phenotype is not discriminating and, most importantly, for the forms associated with a high risk of developing hematologic malignancies. 27 Genotyping carried out with next-generation sequencing (NGS) is a comprehensive and cost-effective strategy for the diagnosis of IPFDs 25, 26 provided that its results are evaluated critically by a multidisciplinary team in light of clinical and laboratory phenotypic data.
| D IAG NOS IS OF CLINI C ALLY RELE VANT PL ATELE T FUN C TION DISORDER S
Hereditary platelet function disorders are a very heterogeneous group of haemorragic diseases, and for several of them, the causative molecular defect is still unknown. In this review, they are classified according to the main function of the defective protein generated by the mutated gene or, when this is not known, to the main structural or functional platelet abnormality ( Table 2 ).
| Disorders of the adhesive protein receptors
Platelets have surface receptors for adhesive proteins of the sub- TA B L E 1 (Continued) α /δ storage pool deficiency Deficiency of platelet α-and δ-granules ND
4-Signal transduction proteins defects
Cytosolic phospholipase A 2α defect PLA2 enzyme PLA2G4A
Cyclo-oxygenase 1 deficiency COX-1 enzyme ND
Thromboxane synthase deficiency Tx synthase enzyme TBXAS1
Phospholipase C deficiency PLC-β2 ND
PKA defect cAMP-dependent protein kinase A PRKAGG

G proteins defects Gαs protein GNAS/ RGS2 Leukocyte adhesion deficiency-III (LAD-III) Kindlin-3 FERMT3
CalDAG-GEFI defect Guanine nucleotide exchange factor for the small GTPase Rap1
RASGRP2
Src defect Tyrosine kinase Src SRC
5-Defects of transcription factors
Familial platelet disorder with associated myeloid malignancy (FPD/AML)
Haematopoietic transcription factor RUNX1
FLI1-related δ granule defect Haematopoietic transcription factor FLI1 (SVNs)
GATA1-defect Haematopoietic transcription factor GATA1
GFI1B-related defect
Haematopoietic transcription factor GFI1B Decreased or absent expression of the GPIb/IX/V complex, due to mutations in the GP1BA, GP1BB or GP9 genes, gives rise to the The DiGeorge or velocardiofacial syndrome (VCF) is an autosomal dominant genetic disorder characterized by a broad phenotypic spectrum (eg, heart malformations, facial dysmorphisms, and immune deficiency) due to a chromosomal deletion involving the GP1BB gene and is characterized by macrothrombocytopenia, reduced expression of platelet GPIb/IX/V and, in only a minority of subjects (30%), reduced or absent agglutination by ristocetin. 29 Defects of GPVI and α 2 β 1 have been described in few patients with mild to severe mucocutaneous bleeding, normal platelet count and morphology or mild macrothrombocytopenia, absent aggregation in response to collagen, or to collagen-related peptide (CRP) and convulxin, and reduced platelet surface expression of α 2 β 1 or GPVI by flow cytometry and/or SDS-PAGE.
6-Defects of cytoskeletal proteins
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Defect of platelet GPVI is an autosomal recessive disorder caused by GP6 gene variants while the defect of α 2 β 1 is transmitted in an autosomal dominant manner but no variants have been identified so far in the genes encoding the 2 subunits of the receptor. 
| Abnormalities of platelet granules
Under the name of platelet storage pool disease (SPD), a group of disorders characterized by a decrease in platelet α-and/or δ-granules are indicated. Three subtypes of SPD have been described:
α-granules deficiency (α-SPD), δ-granules deficiency (δ-SPD), and the combined deficiency of α-and δ-granules (αδ-SPD).
Gray platelet syndrome (GPS) is a rare disease characterized by mild thrombocytopenia, slightly enlarged platelets with a ghost-like, gray appearance on May-Grünwald Giemsa-stained blood smears.
Some GPS patients exhibit a defective activation by thrombin and/ or collagen, while progressive bone marrow fibrosis and increased vitamin B12 in plasma are typical, although unexplained, findings. 
8-Enhanced platelet fibrinolytic activity
Quebec platelet disorder Urokinase-type activator PLAU (duplication)
9-Unclassified
Primary secretion defect Primary protein abnormality unknown ND
TA B L E 2 (Continued)
Typically α-granule proteins are reduced, like fibrinogen and VWF.
Also P-selectin is reduced, although in some cases it was reported to be normal. 31 Gray platelet syndrome is caused by mutations in NBEAL2 and GFI1B and both autosomal recessive and autosomal dominant inheritance have been reported.
Large platelets and reduced α-granules are also a feature of patients with the arthrogryposis, renal dysfunction, and cholestasis (ARC) syndrome, an autosomal recessive multisystem disorder characterized by neonatal cholestatic jaundice, renal tubular leak, hypotoniarelated arthrogryposis, failure to thrive, and death within the first year of life. Platelet P-selectin expression is severely decreased.
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The Paris-Trousseau syndrome is due to the 11q23 deletion involving the gene FLI1 and is associated with moderate to severe thrombocytopenia with giant alpha-granules in platelets that fail to release their contents upon stimulation with thrombin. A subtype of δ-SPD characterized by reduced platelet ADP but normal serotonin content associated with a deficiency of the δ-granule MRP4 (ABCC4) transporter, has been described. HPS is an autosomal recessive syndrome characterized by oculocutaneous albinism, with nystagmus and visual acuity loss, moderate/severe bleeding diathesis and, in some cases, pulmonary fibrosis, granulomatous colitis, and immunodeficiency. 33 CHS is an autosomal recessive disorder affecting multiple organs and associated with oculocutaneous albinism, severe immunodeficiency and progressive neurologic dysfunction. 33 
| Defects of signal transduction proteins
Signal includes a number of biochemical intraplatelet processes triggered by the interaction of agonists with specific platelet receptors and resulting in platelet aggregation and secretion. The link between surface receptors and the cytoplasmic effector enzymes is provided by G proteins.
Inherited platelet signal transduction defects are a poorly defined group of disorders and although it has been suggested that they may represent a significant fraction of platelet disorders characterized by abnormal secondary wave of aggregation and decreased granule release but a normal α-and δ-granule content. These disorders include defects of cytosolic phospholipase A 2α (cPLA 2α ), cyclo-oxygenase-1 (COX-1), thromboxane synthase, phospholipase C-β 2 , PKA, or tyrosine phosphorylation. Moreover, defects of several G proteins including Giα, Gq/ 11 α, G 12/13 α, and Gsα, the latter associated with syndromic manifestations, have been described. , as well as variants in the gene ANKRD26, that however is not a TF but a protein that mediates protein-protein interactions and the function of which in platelets has not been clarified yet.
| Defects of cytoskeletal proteins
Defects in cytoskeletal proteins, mainly a cause of thrombocytopenia, can also perturb platelet function. GPIb, GPIa, and GPIIb-IIIa, impaired GPIIb-IIIa activation, defective platelet aggregation and expression of P-selectin in response to thrombin. 42 However, the laboratory characterization of the platelet dysfunction in WAS/XLT is rendered difficult by the severe microthrombocytopenia.
Homozygous variants of the FYB gene, encoding for the adhesion and degranulation-promoting adaptor protein (ADAP), cause mild microthrombocytopenia, increased expression of P-selectin and PAC-1 on resting platelets but impaired activation upon stimulation, and mildly reduced platelet adhesion to fibrinogen and VWF. 43 Filamin A defects caused by mutations in the X-linked FLNA gene are responsible for a wide spectrum of rare diseases, the most frequent of which is periventricular nodular heterotopia (FLNA-PVNH).
Patients have mild macrothrombocytopenia and impaired platelet aggregation and secretion induced by collagen and convulxin due to a defect of the collagen receptor glycoprotein VI (GPVI). Platelet anisocytosis, with both giant and normal platelets, giant α-granules, and absence of FLNa from a fraction (~20%) of the platelet population at immunofluorescence address the diagnosis, which needs to be confirmed by molecular genetic analysis. 44 
| Abnormalities of membrane phospholipids
Upon platelet activation negatively charged phospholipids, normally present in the inner membrane bilayer, are exposed on the outer layer and provide a surface for activation of coagulation factors leading to the formation of the tenase and prothrombinase complexes and to the generation of thrombin, the key enzyme of blood coagulation triggering platelet activation, to the formation of fibrin and to inhibition of fibrinolysis. 
| Enhanced platelet fibrinolytic activity
The Quebec platelet disorder (QPD) is an autosomal dominant disorder due to a tandem duplication of the gene PLAU encoding for urokinase plasminogen activator, which results in increased accumulation of urokinase-type plasminogen activator (uPA) in platelet α-granules causing the degradation of granular proteins. The increased fibrinolytic activity upon release of α-granules content is the cause of bleeding, with abnormally high release of uPA and accelerated clot lysis, and typically the bleeding diathesis is exquisitely sensitive to antifibrinolytic agents. A characteristic laboratory finding is a reduced level of platelet α-granule clotting factor V with normal plasma factor V. Genetic testing is mandatory for diagnosis. 48 
| Unclassified abnormalities
Any mild bleeding disorders associated with impaired platelet secretion but a normal granular content have been defined as primary secretion defect (PSD). The platelet defect is heterogeneous, with reduced secretion and, although not always, secondary wave aggregation.
Patients with PSD display abnormalities of platelet function, which are similar to those of carriers of heterozygous variants of the P2Y 12 receptor, suggesting that at least a fraction of patients labeled as PSD are indeed heterozygous P2Y 12 defects. 49 It may be expected that with the growing knowledge on the platelet function mechanisms and of the genes regulating platelet function, this disease group will progressively shrink.
| CON CLUS IONS
Inherited platelet function disorders represent a significant fraction of all the bleeding diatheses. Despite their relative frequency their diagnosis is still cumbersome.
An appropriate diagnostic approach based on an accurate clinical evaluation and a streamlined panel of laboratory tests of increasing complexity allows diagnosis in a large part of the cases. The systematic application of rational diagnostic algorithms, together with a continuous effort to improve standardization of the available platelet laboratory tests, will probably increase the fraction of patients with an unknown mucocutaneous bleeding disorder who will be diagnosed with a specific IPFD, expanding our clinical knowledge on these bleeding diatheses, and possibly allowing to unravel novel forms. Correct diagnosis can address prompt and appropriate treatment and minimize the significant bleeding risk associated with IPFDs.
4
ACK N OWLED G EM ENTS
This work was supported in part by grants to P.G. from Telethon foundation (protocol # GGP10155 and protocol # GGP15063) and by a fellowship to E.F. from Fondazione Umberto Veronesi.
O RCI D
P. Gresele http://orcid.org/0000-0001-5365-8445
